<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/31BAAEA1-1BCB-4D42-B1B3-4FC2539E6F43"><gtr:id>31BAAEA1-1BCB-4D42-B1B3-4FC2539E6F43</gtr:id><gtr:name>Public Health England</gtr:name><gtr:address><gtr:line1>Porton Down</gtr:line1><gtr:line4>Salisbury</gtr:line4><gtr:line5>Wiltshire</gtr:line5><gtr:postCode>SP4 0JG</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EA6D79B-D8F2-4357-B9ED-EE9ADC0C767B"><gtr:id>3EA6D79B-D8F2-4357-B9ED-EE9ADC0C767B</gtr:id><gtr:name>National Institute for Public Health and Environment (RIVM)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7035AE5D-F006-4762-9959-D965363291F6"><gtr:id>7035AE5D-F006-4762-9959-D965363291F6</gtr:id><gtr:name>Merck</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/58930F3F-9B16-4DC2-833F-C72033E77A1E"><gtr:id>58930F3F-9B16-4DC2-833F-C72033E77A1E</gtr:id><gtr:name>Boston Children's Hospital</gtr:name><gtr:address><gtr:line1>Boston Childrens Hospital</gtr:line1><gtr:line2>Karp Building</gtr:line2><gtr:line3>9th floor, Rm 09210 1 Blackfan Circle</gtr:line3><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/49FFE305-71E4-41B1-87AC-8E58220B1F28"><gtr:id>49FFE305-71E4-41B1-87AC-8E58220B1F28</gtr:id><gtr:name>Novartis Institutes for Biomedical Research (NIBR)</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/6083E7FB-0220-4F5F-97B0-7F6113B49A0C"><gtr:id>6083E7FB-0220-4F5F-97B0-7F6113B49A0C</gtr:id><gtr:name>MRC Unit, The Gambia</gtr:name><gtr:address><gtr:line1>MRC Laboratories, The Gambia</gtr:line1><gtr:line2>Atlantic Road PO Box 273</gtr:line2><gtr:line4>Fajara</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>Gambia</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6083E7FB-0220-4F5F-97B0-7F6113B49A0C"><gtr:id>6083E7FB-0220-4F5F-97B0-7F6113B49A0C</gtr:id><gtr:name>MRC Unit, The Gambia</gtr:name><gtr:address><gtr:line1>MRC Laboratories, The Gambia</gtr:line1><gtr:line2>Atlantic Road PO Box 273</gtr:line2><gtr:line4>Fajara</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>Gambia</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/31BAAEA1-1BCB-4D42-B1B3-4FC2539E6F43"><gtr:id>31BAAEA1-1BCB-4D42-B1B3-4FC2539E6F43</gtr:id><gtr:name>Public Health England</gtr:name><gtr:address><gtr:line1>Porton Down</gtr:line1><gtr:line4>Salisbury</gtr:line4><gtr:line5>Wiltshire</gtr:line5><gtr:postCode>SP4 0JG</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EA6D79B-D8F2-4357-B9ED-EE9ADC0C767B"><gtr:id>3EA6D79B-D8F2-4357-B9ED-EE9ADC0C767B</gtr:id><gtr:name>National Institute for Public Health and Environment (RIVM)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7035AE5D-F006-4762-9959-D965363291F6"><gtr:id>7035AE5D-F006-4762-9959-D965363291F6</gtr:id><gtr:name>Merck</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/58930F3F-9B16-4DC2-833F-C72033E77A1E"><gtr:id>58930F3F-9B16-4DC2-833F-C72033E77A1E</gtr:id><gtr:name>Boston Children's Hospital</gtr:name><gtr:address><gtr:line1>Boston Childrens Hospital</gtr:line1><gtr:line2>Karp Building</gtr:line2><gtr:line3>9th floor, Rm 09210 1 Blackfan Circle</gtr:line3><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/49FFE305-71E4-41B1-87AC-8E58220B1F28"><gtr:id>49FFE305-71E4-41B1-87AC-8E58220B1F28</gtr:id><gtr:name>Novartis Institutes for Biomedical Research (NIBR)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/E89DF462-9EA4-4042-B006-DC19F73B5B9E"><gtr:id>E89DF462-9EA4-4042-B006-DC19F73B5B9E</gtr:id><gtr:firstName>Beate</gtr:firstName><gtr:surname>Kampmann</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/A46886AF-06E9-49E1-BF77-96A53F3F6C48"><gtr:id>A46886AF-06E9-49E1-BF77-96A53F3F6C48</gtr:id><gtr:firstName>Ed</gtr:firstName><gtr:surname>Clarke</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_UP_A900_1115"><gtr:id>C1DAB5F9-5251-4C01-9C3F-61A3E234691E</gtr:id><gtr:title>Studies to understand the response of the infant?s immune system to infectious diseases and vaccines</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_UP_A900_1115</gtr:grantReference><gtr:abstractText>Despite progress overall in reducing the number of children dying before they reach the age of five, deaths in the first year of life and even more strikingly in the first month of life have not fallen in the same way. At this age many babies die as the result of infections.
The research being carried out in the infant immunology group aims to reduce deaths from infection in this most vulnerable group though better understanding the way the immune (or defence) system works.
We want to understand the best possible ways to give some of the vaccine we already have available. This might include giving vaccine to mums so that the immunity they generate (the antibodies) can protect a baby as soon as the baby is born (before the baby can be vaccinated themselves). We also want to know how the baby?s immune system responds when it comes across an infection. If understood this better we might be able to improve these response, for example with new vaccines, so the baby would not become unwell. Finally we carry out research which gives us a better understanding of how vaccines themselves working in babies. This research includes new vaccines against malaria, HIV and TB as well as established vaccines like the pneumococcal vaccine. Understanding better the vaccines we have should allow the next generation of vaccines to be designed even more effectively so that less newborns and infants die needlessly.</gtr:abstractText><gtr:technicalSummary>Millennium Development Goal 4 sets out to reduce mortality in children under five-years of age. Despite progress with this overall, including in many countries across sub-Saharan Africa, mortality in infancy and in particular in newborns has so far been comparatively resistant to intervention. Although the reasons for this are multi-factorial, many deaths in this period occur as a result of infections. Consequently, understanding the distinct way in which infants respond to infections and vaccines, facilitating the rational development of novel interventions to protect newborns is a top global health priority. These areas are the focus of current research within infant immunology.
Objectives:
To characterise the key elements of the immune response to given pathogens (e.g. pneumococcus, staphylococcus) which may be associated with the development of natural immunity to these agents in order to facilitate the develop novel protective strategies
To describe, at both a cellular and a humoral level, the immunity generated by currently licensed (e.g. rotavirus) as well as experimental (e.g. malaria, HIV, TB) vaccines in order to guide future rational vaccine development 
To establish the optimum regimens for the use of current vaccines (e.g. inactivated poliovirus vaccine, pneumococcal conjugate vaccines) which will maximise the protection of infants while also ensuring the logistical challenges of vaccine delivery on a large scale (e.g. through using fractional doses, novel delivery methods, maternal immunisation, multi-dose vials) are met
Methodology:
These critical objectives are being addressed across a series of maternal and infant cohorts.
A combination of interventional studies, including GCP-clinical vaccine trials, as well as longitudinal observational studies, is used according to the questions being addressed. We have the established capacity to recruit mothers antenatally allowing newborns to be followed right from delivery. We also recruit infants over the first year of life as they are presented for their routine immunisations
A range of laboratory approaches are used including large-scale serological studies monitoring correlates of vaccine induced protection, as well detailed immunological investigations. Such studies, which are often nested within larger scale trials, use techniques including multi-parameter flow-cytometry, ELISpot assays, evaluation of cytokines and antibodies using Luminex-based multi-analyte technology.
Impact
The findings of certain key studies (e.g. inactivated poliovirus vaccine trial) are expected to directly influence WHO policy over the coming year. Other work is focussed on studying pathogens (e.g. pneumococcus, malaria, rotavirus) which remain at the top of the research agenda internationally and address question recognised to be high priority.</gtr:technicalSummary><gtr:fund><gtr:end>2018-01-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2011-04-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>4435721</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Merck</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>Merck Vaccines</gtr:description><gtr:id>3A80AAF4-04D1-4229-9EFA-9763DA8E3BE2</gtr:id><gtr:impact>Nil as yet - trial underway</gtr:impact><gtr:outcomeId>58c1959ce967f9.32389978-1</gtr:outcomeId><gtr:partnerContribution>As part of a clinical trial of HPV vaccines we will provide serum samples to Merck to analyse on their multiplex based serology platform which has been used in past efficacy trial of the vaccine. The results will be provided to us (MRC Unit The Gambia) for analysis.</gtr:partnerContribution><gtr:piContribution>As part of a clinical trial of HPV vaccines we will provide serum samples to Merck to analyse on their multiplex based serology platform which has been used in past efficacy trial of the vaccine. The results will be provided to us (MRC Unit The Gambia) for analysis.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Novartis Institutes for BioMedical Research (NIBR)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Novartis Vaccines Institute for Global Health (NVGH)</gtr:department><gtr:description>Novartis Vaccine development</gtr:description><gtr:id>CF566985-4728-401C-BFC4-C69F95369103</gtr:id><gtr:impact>manuscript in progress</gtr:impact><gtr:outcomeId>YejVnqTre5E-1</gtr:outcomeId><gtr:partnerContribution>funding for consumables</gtr:partnerContribution><gtr:piContribution>generated data for pertussis seroprevalence</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Child Health</gtr:department><gtr:description>ICH London Goldblatt lab</gtr:description><gtr:id>BB01175D-D8DC-44BE-ADA9-C0E2C39F9FC0</gtr:id><gtr:impact>1 shared PhD studentship, 
scientific workshop at MRC The Gambia
input into senior appointments</gtr:impact><gtr:outcomeId>RHwAr4v9KRJ-1</gtr:outcomeId><gtr:partnerContribution>scientific exchange re pneumococcal immunisation policies, practice and research, sharing of reagents and assay development</gtr:partnerContribution><gtr:piContribution>scientific exchange re pneumococcal immunisation policies, practice and research, sharing of reagents and assay development</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Boston Children's Hospital</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Harvard Levy lab</gtr:description><gtr:id>CF504637-F03E-4C67-9003-F8D2347E693E</gtr:id><gtr:impact>publication by Burl et al</gtr:impact><gtr:outcomeId>bKGtNvPjTDb-1</gtr:outcomeId><gtr:partnerContribution>contributed research samples</gtr:partnerContribution><gtr:piContribution>exchange of staff and technology</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Child Health</gtr:department><gtr:description>Harvard Levy lab</gtr:description><gtr:id>E205C931-451F-45F5-808B-ADF0F2C55210</gtr:id><gtr:impact>publication by Burl et al</gtr:impact><gtr:outcomeId>bKGtNvPjTDb-2</gtr:outcomeId><gtr:partnerContribution>contributed research samples</gtr:partnerContribution><gtr:piContribution>exchange of staff and technology</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institute for Public Health and Environment (RIVM)</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:department>Centre for Infectious Diseases, Epidemiology and Surveillance</gtr:department><gtr:description>RIVM Holland</gtr:description><gtr:id>332C8D34-CA11-4163-88B1-97F329DF6BBB</gtr:id><gtr:impact>1 manuscript submitted, 1 in preparation</gtr:impact><gtr:outcomeId>DfDshfFByYT-1</gtr:outcomeId><gtr:partnerContribution>facilitating Tec Transfer to MRC by hosting 2 technicians</gtr:partnerContribution><gtr:piContribution>analysis of samples at MRC using RIVM technology, following successful tec transfer from RIVM
results on pertussis of interest to RIVM epidemiologists</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Public Health England</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Public Health Engalnd</gtr:description><gtr:id>0817B060-41C8-4C9D-9B82-7524A04948C1</gtr:id><gtr:impact>Presentation of clinical trial results and World Health Organisation Meeting</gtr:impact><gtr:outcomeId>5464d145078118.27379804-1</gtr:outcomeId><gtr:partnerContribution>Processing of clinical trial serum samples for serological analysis</gtr:partnerContribution><gtr:piContribution>Provision of clinical trial serum samples</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Inaugural lecture</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>F475D801-FBCD-4EE7-9B26-D0F8C359E6E2</gtr:id><gtr:impact>Travel with T cells, now on YouTube

inerest in academic medicine by GCSE-level students, several University students requesting mentorship</gtr:impact><gtr:outcomeId>Xtsp4briKxC</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Community sensitisation events</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>7E4E3D42-98D2-4A8A-B8C9-D572B3C0E9DB</gtr:id><gtr:impact>The community sensitisation events are regularly conducted to inform past, present and future participants in our research on the results of previous studies and upcoming new research studies and clinical trials. They serve as a link to the community decision makers and are well supported by community members and MRC researchers.

Increased participation in clincial trials and ongoign research</gtr:impact><gtr:outcomeId>545656a3a7df36.89185575</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2010,2011,2012,2013,2014</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>370000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>PhD studentship Dr Battersby</gtr:description><gtr:end>2016-02-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>FF53770F-199D-4ABA-9BF8-80B1C0F7CF17</gtr:id><gtr:outcomeId>axe6hfX2brF</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>55000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Global Health Wellcome Trust fellowship Dr LeDoare</gtr:description><gtr:end>2014-09-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>396B1190-D5AB-43A9-9702-990ADA211481</gtr:id><gtr:outcomeId>hwhABGkxAZN</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>195000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Maternal Men A vaccination</gtr:description><gtr:end>2018-01-02</gtr:end><gtr:fundingOrg>Meningitis Research Foundation</gtr:fundingOrg><gtr:id>018F3FB3-6CD1-4D83-A00A-CD2F3C86AA44</gtr:id><gtr:outcomeId>56dd7b6d912e99.44782584</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>247000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Wellcome Trust Research Training Fellowship</gtr:department><gtr:description>Wellcome Trust Training Fellowship</gtr:description><gtr:end>2017-09-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>2649BEBB-ED89-45EA-BF93-E4EF4A4F87B7</gtr:id><gtr:outcomeId>545652d3bfa2b4.36985616</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1300000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Department for International Development (DfID)</gtr:department><gtr:description>Clinical Trial scheme MRC/DFID/WT</gtr:description><gtr:end>2018-01-02</gtr:end><gtr:fundingOrg>Government of the UK</gtr:fundingOrg><gtr:id>1A49854A-0184-4316-9941-40261874EACB</gtr:id><gtr:outcomeId>545bd4aae931d6.51902594</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>350000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>Al Thrasher Award</gtr:description><gtr:end>2017-11-02</gtr:end><gtr:fundingOrg>Thrasher Research Fund</gtr:fundingOrg><gtr:id>ACA9C707-EC46-4293-9264-4A32EE5B4AAF</gtr:id><gtr:outcomeId>545653808049c6.60624468</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2000000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>Project grant Polio trial BMGF</gtr:description><gtr:end>2016-07-02</gtr:end><gtr:fundingOrg>Bill and Melinda Gates Foundation</gtr:fundingOrg><gtr:id>98029D63-0356-4064-AA23-9079404F17AA</gtr:id><gtr:outcomeId>545653cf3b6616.37873321</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>4700000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>N/A</gtr:description><gtr:end>2018-09-02</gtr:end><gtr:fundingOrg>PATH Vaccine Solutions</gtr:fundingOrg><gtr:id>25128A37-260B-43F0-8BCA-CAF0633FCEF5</gtr:id><gtr:outcomeId>58c158a07301e1.15137523</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>350000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>Investigator initiated proposal</gtr:description><gtr:end>2014-03-02</gtr:end><gtr:fundingOrg>Pfizer Ltd</gtr:fundingOrg><gtr:id>3CB6FD67-7522-4F46-9E4A-9B7C673CCEA9</gtr:id><gtr:outcomeId>545bd3510cb2d4.17008784</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2012-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1900000</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>PCV10 Clinical Vaccine Trial Scheme</gtr:description><gtr:end>2016-07-02</gtr:end><gtr:fundingOrg>PATH</gtr:fundingOrg><gtr:id>37F4B1B1-F9FD-4B5B-A4B3-FEE71870F94D</gtr:id><gtr:outcomeId>56dd7ad64bf648.40542045</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2013-09-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Maternal Immunization Pharmacovigilance - Landscape Review - A Roadmap for Program Development in Low and Middle Income Countries</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>54AAFDFB-0A85-495C-8543-A0FC91EE8B2A</gtr:id><gtr:impact>The document resulting from this advisory committee consultation is expected to be used to focus future work to measure health impacts in expectant mothers receiving vaccines in low and middle income countries as well as to direct the development of the otherwise fledgling regulatory framework globally</gtr:impact><gtr:outcomeId>58c152148b29a0.60739400</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Novartis maternal immunisation strategy board</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>7436BD94-A3C4-4D02-AA4D-43A85BA950C4</gtr:id><gtr:impact>the advice from the group of which I was an scientific member led to critical appraisal within industry which vaccines to push forward for maternal immunisation.</gtr:impact><gtr:outcomeId>NecBRT1mmNa</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Pfizer GAVI advisory board</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>98CF273A-B814-4087-8910-631084F612E7</gtr:id><gtr:impact>possible impact, as Nigeria haas now introduced the PcV vaccine which was advised by the board</gtr:impact><gtr:outcomeId>qfigr2RKRKf</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Member - Bill &amp;amp; Melinda Gates Foundation Expert Advisory Group on Single Dose HPV vaccine scheduling</gtr:description><gtr:geographicReach>Africa</gtr:geographicReach><gtr:id>E5ABD510-7C3A-4425-9350-4042927A6C24</gtr:id><gtr:impact>The expert committee has been set up to drive the research and implementation agenda for single dose HPV vaccine schedules in Low and Middle Income Countries</gtr:impact><gtr:outcomeId>58c15320181e17.35264091</gtr:outcomeId><gtr:type>Membership of a guideline committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>introduction of new vaccine in The Gambia EPI</gtr:description><gtr:geographicReach>Local/Municipal/Regional</gtr:geographicReach><gtr:id>1B1D659D-E9F2-4654-8F4E-24589A2B6D59</gtr:id><gtr:impact>In August 2013 the Government of The Gambia introduced the Rotavirus vaccine into the EPI schedule. This was amongst other things prompted by data from the MRC Unit showing that rotavirus made a significant contribution to morbidity and mortality in children in The Gambia. The lab work was led by Vaccinology (Dr Antonio)</gtr:impact><gtr:outcomeId>EuoJ5ASurH2</gtr:outcomeId><gtr:type>Implementation circular/rapid advice/letter to e.g. Ministry of Health</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>WHO advisory board</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>47AB305B-F90B-44AA-8F25-BF0842D631E0</gtr:id><gtr:impact>improvements in delivery of clinical services to children exposed to TB by advocating contact tracing for vulnerable groups in the WHO guideline document to which I contributed</gtr:impact><gtr:outcomeId>c53US1AyxbG</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Press panel RCPCH</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>4816DC23-AC97-4C85-AE82-22313EF398D2</gtr:id><gtr:outcomeId>tCBomKswfMn</gtr:outcomeId><gtr:type>Participation in a national consultation</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Prevenar13 is licensed in infants, children and adults but is not licensed in pregnancy. This trial is testing the safety and efficacy against pneumococcal nasopharyngeal carriage of the vaccine in pregnant women and newborns</gtr:description><gtr:id>10444694-AE43-4AEC-AB5E-9FC787BE7571</gtr:id><gtr:impact>The trial is currently underway and data has yet to be analysed.</gtr:impact><gtr:outcomeId>58c191eaca09f7.08205970</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Prevenar13 (licensed vaccine) for use in expectant mothers (unlicensed indication)</gtr:title><gtr:type>Therapeutic Intervention - Vaccines</gtr:type><gtr:url>https://clinicaltrials.gov/ct2/show/NCT02628886</gtr:url><gtr:yearDevCompleted>2017</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>We have recently completed a phase 1/2 trial and a phase 3 licensure trial is now planned</gtr:description><gtr:id>0D9CE254-5317-45C8-A91E-9332CC6558B9</gtr:id><gtr:impact>The phase 1/2 trial completed and the phase 3 trial planned aim to result in the licensure of the first generic pneumococcal conjugate vaccine specifically targeting those pneumococcal serotypes prevalent in low and middle income countries</gtr:impact><gtr:outcomeId>58c1939bc538a6.32492558</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>10 valent pneumococcal conjugate vaccine manufactured by the Serum Institute of India (generic for GAVI purchase)</gtr:title><gtr:type>Therapeutic Intervention - Vaccines</gtr:type><gtr:url>https://clinicaltrials.gov/ct2/show/NCT02308540?term=VAC017&amp;rank=1</gtr:url><gtr:yearDevCompleted>2017</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>currently conducting new application of polio vaccine to be given i.m at 9 months with other EPI vaccines
funding: BMGF</gtr:description><gtr:id>9A44EDBB-2A29-423A-9CE7-E3280096AC2C</gtr:id><gtr:impact>trial in progress</gtr:impact><gtr:outcomeId>iXbaGgejQ7q</gtr:outcomeId><gtr:stage>Refinement.  Clinical</gtr:stage><gtr:status>Under active development_distribution</gtr:status><gtr:title>polio vaccine</gtr:title><gtr:type>Therapeutic Intervention - Vaccines</gtr:type><gtr:url>http://clinicaltrials.gov/show/NCT01847872</gtr:url><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>2 needleless devices to administer vaccines are currently under evaluation within Vaccinology/Inf Immunology.
funding: BMGF/PATH</gtr:description><gtr:id>2837C77D-EA86-4C9A-A261-A18E87F7D19D</gtr:id><gtr:impact>trial ongoing</gtr:impact><gtr:outcomeId>qW83WGDJ22y</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Under active development_distribution</gtr:status><gtr:title>polio needleless devices</gtr:title><gtr:type>Therapeutic Intervention - Medical Devices</gtr:type><gtr:url>http://clinicaltrials.gov/show/NCT01847872</gtr:url><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Maternal vaccination trials in low income countries require the development of significant research infrastructure. IN particular we have established an antenatal ultrasound facility within which to undertake gestational ultrasound assessments (not otherwise available in the country) and a framework for the capture and reporting of safety outcomes</gtr:description><gtr:id>2B00BA97-01BA-48FA-9E82-BAB9AAC17CA5</gtr:id><gtr:impact>The platform will be used for future research in this field in The Gambia and is also likely (based on a planned publication related to the development of the platform) to guide researchers elsewhere</gtr:impact><gtr:outcomeId>58c1575c119bd2.58258719</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>The development of a research platform within which to undertake maternal vaccination safety and immunogenicity trials in The Gambia</gtr:title><gtr:type>Improvements to research infrastructure</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>DB15E5F7-4120-4226-AE8A-B85022BFE8BF</gtr:id><gtr:title>The Immunogenicity of Fractional Intradermal Doses of the Inactivated Poliovirus Vaccine Is Associated With the Size of the Intradermal Fluid Bleb.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3bc02dfd10b5ed3768377a6628c07e55"><gtr:id>3bc02dfd10b5ed3768377a6628c07e55</gtr:id><gtr:otherNames>Bibby J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>5aaa3e0324f789.49608110</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EEF57359-CDAE-4277-8EB7-C314F8E49F5F</gtr:id><gtr:title>Maternal immunization as a strategy to decrease susceptibility to infection in newborn infants.</gtr:title><gtr:parentPublicationTitle>Current opinion in infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/16f14cd8f026aea2ff7349b5f4f9a0f9"><gtr:id>16f14cd8f026aea2ff7349b5f4f9a0f9</gtr:id><gtr:otherNames>Lindsey B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0951-7375</gtr:issn><gtr:outcomeId>pm_13512_22_23507974</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B2E14BEF-4420-46EE-AFAF-411C6B19D3FE</gtr:id><gtr:title>The relationship between concentration of specific antibody at birth and subsequent response to primary immunization.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eb717bce2e3d9f5f8e2e0fd9de5431d0"><gtr:id>eb717bce2e3d9f5f8e2e0fd9de5431d0</gtr:id><gtr:otherNames>Jones C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>545bd097c27bc3.52261711</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>158B6EED-36BE-4CDC-9247-757004A763D4</gtr:id><gtr:title>Antibodies against Haemophilus influenzae type b in The Gambia: investigating the extent of protection across age groups.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8630d38a88c3f539cee58b8275068ee2"><gtr:id>8630d38a88c3f539cee58b8275068ee2</gtr:id><gtr:otherNames>Idoko OT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>54564f09e14cc3.35779914</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E453DDC8-E4F0-41AE-B642-8BC2E286E87B</gtr:id><gtr:title>Current understanding of the immune response to tuberculosis in children.</gtr:title><gtr:parentPublicationTitle>Current opinion in infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bb1713935960ba4e6ada861507a76d09"><gtr:id>bb1713935960ba4e6ada861507a76d09</gtr:id><gtr:otherNames>Basu Roy R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0951-7375</gtr:issn><gtr:outcomeId>pm_13512_22_22491144</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>067406B8-290C-43D1-BEDC-D2DAE7A4322C</gtr:id><gtr:title>Specific antibodies against vaccine-preventable infections: a mother-infant cohort study.</gtr:title><gtr:parentPublicationTitle>BMJ open</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eb717bce2e3d9f5f8e2e0fd9de5431d0"><gtr:id>eb717bce2e3d9f5f8e2e0fd9de5431d0</gtr:id><gtr:otherNames>Jones C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2044-6055</gtr:issn><gtr:outcomeId>pm_13512_22_23585389</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1B7D875B-34E8-4EC0-9942-395AD2B05528</gtr:id><gtr:title>Age-dependent maturation of Toll-like receptor-mediated cytokine responses in Gambian infants.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/66a5780653887989616b1c6ad11d85bc"><gtr:id>66a5780653887989616b1c6ad11d85bc</gtr:id><gtr:otherNames>Burl S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_13512_22_21533209</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>61842E78-AA72-4BA6-AB77-12C1E73A2E17</gtr:id><gtr:title>Correlates of protection against human rotavirus disease and the factors influencing protection in low-income settings.</gtr:title><gtr:parentPublicationTitle>Mucosal immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1d427600d7a231127ff9995f95c66a3e"><gtr:id>1d427600d7a231127ff9995f95c66a3e</gtr:id><gtr:otherNames>Clarke E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1933-0219</gtr:issn><gtr:outcomeId>56dd7371848437.66168147</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>40D4FD70-4397-4298-AB3E-46624EE86E40</gtr:id><gtr:title>Polysaccharide-protein conjugate vaccination induces antibody production but not sustained B-cell memory in the human nasopharyngeal mucosa.</gtr:title><gtr:parentPublicationTitle>Mucosal immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/30ca6d269ac39ad504882e1f2a8db863"><gtr:id>30ca6d269ac39ad504882e1f2a8db863</gtr:id><gtr:otherNames>Clarke ET</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1933-0219</gtr:issn><gtr:outcomeId>56dd72d9177602.96662838</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C29CD259-0C94-4148-9CD3-963CF233DA1F</gtr:id><gtr:title>Targeting regulatory T cells to improve vaccine immunogenicity in early life.</gtr:title><gtr:parentPublicationTitle>Frontiers in microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/729ba36d5705e40f5e7c40bd94950457"><gtr:id>729ba36d5705e40f5e7c40bd94950457</gtr:id><gtr:otherNames>Ndure J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1664-302X</gtr:issn><gtr:outcomeId>56dd719a9e13d3.28725920</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0C7FB31E-4737-4C48-9D3E-FCF163BA0228</gtr:id><gtr:title>Maternal HIV infection and antibody responses against vaccine-preventable diseases in uninfected infants.</gtr:title><gtr:parentPublicationTitle>JAMA</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3bdffc049adbcb99401d65c52e5ff669"><gtr:id>3bdffc049adbcb99401d65c52e5ff669</gtr:id><gtr:otherNames>Jones CE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0098-7484</gtr:issn><gtr:outcomeId>pm_13512_22_21304083</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A06AFA7B-62E6-4D47-A114-3441DEF7B29C</gtr:id><gtr:title>Association between functional antibody against Group B Streptococcus and maternal and infant colonization in a Gambian cohort.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f2918f0e3820429f15952099f7448aa4"><gtr:id>f2918f0e3820429f15952099f7448aa4</gtr:id><gtr:otherNames>Le Doare K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>5aaa3e03db89b9.44718794</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DAF97AC0-2155-42A7-9C11-ECF8A462395B</gtr:id><gtr:title>Availability and use of molecular microbiological and immunological tests for the diagnosis of tuberculosis in europe.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a420a8e982eed89eac394624414ca069"><gtr:id>a420a8e982eed89eac394624414ca069</gtr:id><gtr:otherNames>Tebruegge M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>545bcf9ab5bf87.48140214</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0413C252-04E7-471C-9372-F88E32D03084</gtr:id><gtr:title>Achieving comprehensive childhood immunization: an analysis of obstacles and opportunities in The Gambia.</gtr:title><gtr:parentPublicationTitle>Health policy and planning</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bc044d54aab02647920c01b68ec09a5d"><gtr:id>bc044d54aab02647920c01b68ec09a5d</gtr:id><gtr:otherNames>Payne S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0268-1080</gtr:issn><gtr:outcomeId>pm_13512_22_23426974</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F27F5104-5B2F-4AC3-88C1-47259D8D3A4D</gtr:id><gtr:title>Vitamin D in early childhood and the effect on immunity to Mycobacterium tuberculosis.</gtr:title><gtr:parentPublicationTitle>Clinical &amp; developmental immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2f52e5e0c9f11fd5dd2b330505c314eb"><gtr:id>2f52e5e0c9f11fd5dd2b330505c314eb</gtr:id><gtr:otherNames>Battersby AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1740-2522</gtr:issn><gtr:outcomeId>pm_13512_22_22829851</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>50B158ED-BEBB-40C9-8615-679642C84D89</gtr:id><gtr:title>Influence of enteric infections on response to oral poliovirus vaccine: a systematic review and meta-analysis.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6d7533d199dc05be90709dffd1cf0467"><gtr:id>6d7533d199dc05be90709dffd1cf0467</gtr:id><gtr:otherNames>Parker EP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>545bcfebe57f41.92872170</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>90B8E999-4BF2-423A-BB5A-CEB42CFC5089</gtr:id><gtr:title>Safety and immunogenicity of inactivated poliovirus vaccine when given with measles-rubella combined vaccine and yellow fever vaccine and when given via different administration routes: a phase 4, randomised, non-inferiority trial in The Gambia.</gtr:title><gtr:parentPublicationTitle>The Lancet. Global health</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1d427600d7a231127ff9995f95c66a3e"><gtr:id>1d427600d7a231127ff9995f95c66a3e</gtr:id><gtr:otherNames>Clarke E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2214-109X</gtr:issn><gtr:outcomeId>58c155634350b1.55361375</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6A5CF02B-1EF9-4F37-B9A1-8B1444D9BDDD</gtr:id><gtr:title>Maternal and neonatal pneumococcal vaccination - where are we now?</gtr:title><gtr:parentPublicationTitle>Expert review of vaccines</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1d427600d7a231127ff9995f95c66a3e"><gtr:id>1d427600d7a231127ff9995f95c66a3e</gtr:id><gtr:otherNames>Clarke E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1476-0584</gtr:issn><gtr:outcomeId>58c1556307b4f5.52551171</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0D8AAE85-5262-47EA-87F7-A523786AEE81</gtr:id><gtr:title>Immunization status of children with HIV: failure to protect a vulnerable population.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1247f44d77e0dac0d582bf988fd90e36"><gtr:id>1247f44d77e0dac0d582bf988fd90e36</gtr:id><gtr:otherNames>Zinna S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>pm_13512_22_21729230</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>922C23C8-FD41-405F-8BC4-A950539861B5</gtr:id><gtr:title>Polysaccharide-specific memory B cells generated by conjugate vaccines in humans conform to the CD27+IgG+ isotype-switched memory B Cell phenotype and require contact-dependent signals from bystander T cells activated by bacterial proteins to differentiate into plasma cells.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/30ca6d269ac39ad504882e1f2a8db863"><gtr:id>30ca6d269ac39ad504882e1f2a8db863</gtr:id><gtr:otherNames>Clarke ET</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>56dd72d8cf7213.39833965</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>495F73FD-0400-4836-A9B5-3F3C1896BE82</gtr:id><gtr:title>Negative Correlation between Circulating CD4FOXP3CD127Regulatory T Cells and Subsequent Antibody Responses to Infant Measles Vaccine but Not Diphtheria-Tetanus-Pertussis Vaccine Implies a Regulatory Role.</gtr:title><gtr:parentPublicationTitle>Frontiers in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/729ba36d5705e40f5e7c40bd94950457"><gtr:id>729ba36d5705e40f5e7c40bd94950457</gtr:id><gtr:otherNames>Ndure J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1664-3224</gtr:issn><gtr:outcomeId>5aaa3e03709330.25873756</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0DE349F7-2912-417B-89AE-18EFCCA0B269</gtr:id><gtr:title>Memory B cell response to a PCV-13 booster in 3.5year old children primed with either PCV-7 or PCV-13.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2104b231abdb8320285655018612a056"><gtr:id>2104b231abdb8320285655018612a056</gtr:id><gtr:otherNames>Tr?ck J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>5aaa3e039f2025.72540015</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1EE85CF3-058E-49C1-8900-D52778AFE9BD</gtr:id><gtr:title>Acceptability of intranasal live attenuated influenza vaccine, influenza knowledge and vaccine intent in The Gambia.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a9b1d85c688f62ea6f8460ca59dd9d92"><gtr:id>a9b1d85c688f62ea6f8460ca59dd9d92</gtr:id><gtr:otherNames>Armitage EP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>5aaa3c289d4c66.98973843</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5AE00BDC-CF16-469A-9A0D-542483A00F0A</gtr:id><gtr:title>The impact of pre-existing antibody on subsequent immune responses to meningococcal A-containing vaccines.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8630d38a88c3f539cee58b8275068ee2"><gtr:id>8630d38a88c3f539cee58b8275068ee2</gtr:id><gtr:otherNames>Idoko OT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>54564fe4a745c7.77138694</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CA843F60-2204-4F75-9F53-642A13A7F715</gtr:id><gtr:title>Serological response to 13-valent pneumococcal conjugate vaccine in children and adolescents with perinatally acquired HIV infection.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3da9d74f94d2e484bd71b0b6e6e2f9d6"><gtr:id>3da9d74f94d2e484bd71b0b6e6e2f9d6</gtr:id><gtr:otherNames>Bamford A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>54564f8e488d78.84208837</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>622CA8FA-9B5E-47F1-9695-B6282FCE4636</gtr:id><gtr:title>Breast milk and Group B streptococcal infection: vector of transmission or vehicle for protection?</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f2918f0e3820429f15952099f7448aa4"><gtr:id>f2918f0e3820429f15952099f7448aa4</gtr:id><gtr:otherNames>Le Doare K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>54565039784582.12337305</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>400A772C-CDCD-4FE0-B999-172752D6D6CC</gtr:id><gtr:title>Early phase clinical trials with human immunodeficiency virus-1 and malaria vectored vaccines in The Gambia: frontline challenges in study design and implementation.</gtr:title><gtr:parentPublicationTitle>The American journal of tropical medicine and hygiene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5bd0b08c7569d3fbb892d3070c540098"><gtr:id>5bd0b08c7569d3fbb892d3070c540098</gtr:id><gtr:otherNames>Afolabi MO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0002-9637</gtr:issn><gtr:outcomeId>545bcfec8a23e8.24467939</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>34E51888-D008-4A71-B2C5-577ABE5B21C5</gtr:id><gtr:title>Soluble ecto-5'-nucleotidase (5'-NT), alkaline phosphatase, and adenosine deaminase (ADA1) activities in neonatal blood favor elevated extracellular adenosine.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c5ecadab198d28340237929f3d7ba6e1"><gtr:id>c5ecadab198d28340237929f3d7ba6e1</gtr:id><gtr:otherNames>Pettengill M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>pm_13512_22_23897810</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_UP_A900_1115</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>